XASX
VLS
Market cap87mUSD
Dec 04, Last price
2.40AUD
1D
-1.23%
1Q
-0.83%
Jan 2017
84.62%
IPO
1,400.00%
Name
Vita Life Sciences Ltd
Chart & Performance
P/E
14.93
P/S
1.65
EPS
0.16
Div Yield, %
3.96%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
13.37%
Revenues
80m
+7.21%
Net income
9m
-3.26%
CFO
6m
-52.59%
Dividend
Sep 20, 20240.035 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, and Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritional products and nutritional oils; immunity; hair, skin, and nails; liver and digestion; weight management; cardiovascular health; pain and inflammation; pregnancy and breastfeeding; men, women, and children's health; antioxidant; and bones and joints. The company markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||